XML 15 R5.htm IDEA: XBRL DOCUMENT v3.21.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND SHAREHOLDERS' EQUITY - USD ($)
$ in Millions
Total
Total Shareholders' Equity Attributable to Bruker Corporation
Common Stock
Treasury Stock
Additional Paid-In Capital
Retained Earnings
Accumulated Other Comprehensive Income (Loss)
Noncontrolling Interests in Consolidated Subsidiaries
Redeemable Noncontrolling Interest
Balance at beginning of period at Dec. 31, 2019 $ 917.1 $ 906.8 $ 1.7 $ (543.8) $ 199.7 $ 1,274.7 $ (25.5) $ 10.3 $ 21.1
Balance (in shares) at Dec. 31, 2019     154,155,798 19,346,577          
Increase (Decrease) in Stockholders' Equity                  
Stock options exercised 0.7 0.7     0.7        
Stock options exercised (in shares)     30,182            
RSU vested (0.1) (0.1)     (0.1)        
RSU vested (in shares)     40,516            
Stock based compensation 3.0 3.0     3.0        
Dividends declared to common stockholders (7.4) (6.2)       (6.2)   (1.2)  
Acquired 80% interest in Hain LifeScience GmbH (1.3) (1.3)       (1.3)     (20.6)
Consolidated net income 10.6 10.5       10.5   0.1  
Other comprehensive income (loss) 2.0 2.2         2.2 (0.2) $ (0.5)
Balance at end of period at Mar. 31, 2020 924.6 915.6 $ 1.7 $ (543.8) 203.3 1,277.7 (23.3) 9.0  
Balance (in shares) at Mar. 31, 2020     154,226,496 19,346,577          
Balance at beginning of period at Dec. 31, 2020 974.3 961.2 $ 1.7 $ (667.0) 216.3 1,406.5 3.7 13.1  
Balance (in shares) at Dec. 31, 2020     151,987,081 22,058,529          
Increase (Decrease) in Stockholders' Equity                  
Stock options exercised 1.2 1.2     1.2        
Stock options exercised (in shares)     65,312            
RSU vested (0.1) (0.1)     (0.1)        
RSU vested (in shares)     21,821            
Stock based compensation 3.4 3.4     3.4        
Shares purchased (32.8) (32.8)   $ (32.8)          
Shares purchased (in shares)     (530,729) 530,729          
Dividends declared to common stockholders (6.1) (6.1)       (6.1)      
Consolidated net income 57.8 56.7       56.7   1.1  
Other comprehensive income (loss) (16.0) (15.8)         (15.8) (0.2)  
Balance at end of period at Mar. 31, 2021 $ 981.7 $ 967.7 $ 1.7 $ (699.8) $ 220.8 $ 1,457.1 $ (12.1) $ 14.0  
Balance (in shares) at Mar. 31, 2021     151,543,485 22,589,258